MetaVia (MTVA) Return on Capital Employed (2016 - 2026)
MetaVia's (MTVA) quarterly Return on Capital Employed came in at 187.88% in Q4 2025, up 7565.0% YoY from 2.45% in Q4 2024, and up 10.91% on a QoQ basis from 210.9% in Q3 2025.
MetaVia (MTVA) Return on Capital Employed (2016 - 2026) Analysis & Trends
MetaVia (MTVA) has 10 years of Return on Capital Employed data on file, last reported at 187.88% in Q4 2025.
- Quarterly Return on Capital Employed rose 7565.0% year-over-year to 187.88% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 187.88% (up 7565.0% YoY) and the FY2025 annual result came in at 170.42%, up 8567.0% from the prior year.
- Return on Capital Employed climbed to 187.88% in Q4 2025, from 210.9% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 0.76% in Q4 2023 to a low of 402.48% in Q3 2021.
- A 5-year average of 177.35% and a median of 168.07% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed surged 22469 bps — and 2025, when it sank 36587 bps.
- Tracing MTVA's Return on Capital Employed over 5 years: stood at 148.25% in 2021, then plunged by 51 bps to 223.93% in 2022, then surged by 100 bps to 0.76% in 2023, then tumbled by 34944 bps to 263.53% in 2024, then rose by 29 bps to 187.88% in 2025.
- The last three Return on Capital Employed figures came in at 187.88% (Q4 2025), 210.9% (Q3 2025), and 309.45% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | -259.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -259.90% |
| Dec 31, 2025 | -187.88% |
| Sep 30, 2025 | -210.90% |
| Jun 30, 2025 | -309.45% |
| Mar 31, 2025 | -398.15% |
| Dec 31, 2024 | -263.53% |
| Sep 30, 2024 | -98.25% |
| Jun 30, 2024 | -103.01% |
| Mar 31, 2024 | -32.28% |
| Dec 31, 2023 | 0.76% |
| Sep 30, 2023 | -75.67% |
| Jun 30, 2023 | -63.71% |
| Mar 31, 2023 | -89.51% |
| Dec 31, 2022 | -223.93% |
| Sep 30, 2022 | -191.10% |
| Jun 30, 2022 | -134.05% |
| Mar 31, 2022 | -108.50% |
| Dec 31, 2021 | -148.25% |
| Sep 30, 2021 | -402.48% |
| Jun 30, 2021 | -264.37% |